Implementation of AUC-Guided Vancomycin Dosing: What Role Remains for Trough-Only Monitoring? A Retrospective, Cohort...

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• 2020 guidelines recommended AUC-guided vancomycin dosing for serious MRSA infections to reduce AKI.
• Previous trough-only dosing targeted 15-20 mg/L.

Purpose of the Study:

• To compare AUC-guided vancomycin dosing with trough-only dosing (10-20 mg/L).
• To determine if AUC-guided dosing reduces AKI and improves clinical outcomes, including non-invasive infections.

Main Methods:

• Retrospective, single-center cohort study over 12 months.
• Compared Bayesian software-guided AUC-dosing with trough-only dosing.
• Collected data on demographics, co-morbidities, nephrotoxins, drug exposure, and outcomes.

Main Results:

• AKI incidence was similar: 7.65% (AUC-guided) vs 6.06% (trough-only).
• AUC-guided dosing significantly reduced total daily dose (2.29 vs 2.54 g/day).
• No significant difference in cumulative dose, duration, length of stay, or overall outcomes.

Conclusions:

• AUC-guided vancomycin dosing did not reduce AKI or improve patient outcomes compared to trough-only dosing.
• Lower average trough concentrations may be effective for nonbacteremic skin soft tissue infections (SSTI).
• Further research into vancomycin dosing strategies is suggested.